Immunohistochemical Expression of Epithelial Cell Adhesion Molecule (EpCAM) in Epithelial Ovarian Carcinoma

Recruiting

• Conditions: Ovarian Carcinoma

• Registration Number: NCT05576519
• Lead Sponsor: Sohag University

Brief Summary

Cancer stem cells (CSCs) can undergo self-renewal and differentiation. EpCAM is a 40-kDa type I transmembrane glycoprotein composed of a large extracellular domain, one transmembrane region, and a small intracellular domain of 26 amino acids. Recent insights revealed that it is involved in promoting cancer cell proliferation, migration, and invasiveness. It is used as a diagnostic and prognostic marker. EpCAM has also recently been identified as a marker for CSCs.

Detailed Description

Ovarian carcinoma is one of most frequent cancer in women worldwide. Epithelial ovarian carcinoma is a group of neoplasms with different histologic pictures. Serous carcinoma is the most common type.

Cancer stem cells (CSCs) can undergo self-renewal and differentiation. EpCAM is a 40-kDa type I transmembrane glycoprotein composed of a large extracellular domain, one transmembrane region, and a small intracellular domain of 26 amino acids. It is abundantly expressed by the majority of human epithelial carcinomas, including colorectal, breast, lung, prostate, ovarian, and endometrial cancers. it is overexpressed in various neoplasms. Recent insights revealed that it is involved in promoting cancer cell proliferation, migration, and invasiveness. It is used as a diagnostic and prognostic marker. EpCAM has also recently been identified as a marker for CSCs.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2017-06-01
• Status Verified: 2022-10
• Study First Submitted: 2022-10-08
• Study First Submitted QC: 2022-10-08
• Last Update Submitted: 2022-10-08
• Study First Posted: 2022-10-12
• Last Update Posted: 2022-10-12
• Primary Completion: 2022-11-01
• Study Completion: 2022-12-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 50

Inclusion Criteria

• Patients with epithelial ovarian carcinoma and underwent surgery

Read More

Exclusion Criteria

• • Cases received pre-operative chemotherapy or radiotherapy.
• Cases with insufficient clinical data.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
evaluate EpCAM expression in ovarian carcinoma	1 month	IHC

Trial Locations

Locations (2)

Faculty of Medicine, Sohag University; 🇪🇬 Sohag, Egypt

Faculty of Medicine; 🇪🇬 Sohag, Egypt